by Angela Guess
According to a recent press release, “Litmus Health, a clinical data science platform focused on health-related quality of life, today launched into public beta. The company uses data collected at the point of experience from wearables, smart devices, and home sensors to inform clinical endpoints and guide trial management. Litmus is initially focused on Phase I/II clinical trials. The decision faced by pharma to move forward from Phase II to Phase III is an expensive one, as several hundred million dollars usually hang in the balance. The goal is to get breakthrough treatments to market faster by putting health-related quality of life at the forefront of clinical development. Too often researchers press forward having collected little data on what’s happening outside the clinic, and even then, only across a few dimensions.”
The release goes on, “The Litmus platform supports more than 200 data sources that describe patients’ behavior and environments. The company also draws from a library of validated patient surveys and can easily add new instruments. Researchers are able to customize their data sources and build their unique trial, combining traditional validated surveys with patient-generated remote data. The result is a comprehensive indication of a patient’s health and quality of life at any point in time. Once data are collected, Litmus uses machine learning and other algorithms to align time-series data, integrate multiple orthogonal data sources, and look for correlations between behavior, environment, and patient outcomes.”
Read more at PRWeb.
Photo credit: Litmus Health